US 12,338,205 B2
Crystalline form of 3-((L-valyl) amino)-1-propanesulfonic acid
Jiasheng Lu, Suzhou (CN); Jiamin Gu, Suzhou (CN); Xiang Ji, Suzhou (CN); Xinyong Lv, Suzhou (CN); Juan Peng, Suzhou (CN); and Xianqi Kong, Suzhou (CN)
Assigned to RISEN (SUZHOU) PHARMA TECH CO., LTD., Suzhou (CN)
Appl. No. 17/293,742
Filed by RISEN (SUZHOU) PHARMA TECH CO., LTD., Jiangsu (CN)
PCT Filed Oct. 30, 2019, PCT No. PCT/CN2019/114212
§ 371(c)(1), (2) Date May 13, 2021,
PCT Pub. No. WO2020/098492, PCT Pub. Date May 22, 2020.
Claims priority of application No. 201811347491.1 (CN), filed on Nov. 13, 2018.
Prior Publication US 2022/0002239 A1, Jan. 6, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07C 309/15 (2006.01); A61P 25/28 (2006.01)
CPC C07C 309/15 (2013.01) [A61P 25/28 (2018.01); C07B 2200/13 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A crystalline form of 3-((L-valyl)amino)-1-propanesulfonic acid, characterized in that said crystalline form exhibits characteristic diffraction peaks at 2θ diffraction angles of 9.4°, 11.1°, 15.9°, 17.8°, 18.4°, 21.0°, and 22.5° in an X-ray powder diffraction pattern using Cu-Kα as a radiation source, wherein 2θ has an error range of ±0.2°, and a starting melt temperature of a differential scanning calorimetry curve of said crystalline form is about 301° C. or higher.